Physician profile
Rene Elkin
NPI 1962592378
$185,949.45
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $45K · 2021: $29K · 2022: $150 · 2023: $259 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $1,475 · Food and Beverage: $568 · Consulting Fee: $150 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,600.00 |
| Travel and Lodging | $1,475.21 |
| Food and Beverage | $568.02 |
| Consulting Fee | $150.00 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $81,008.11 | 2019-2021 | |
| Biogen, INC. | $48,270.17 | 2019-2023 | Tysabri |
| Tg Therapeutics, INC. | $26,427.97 | 2023-2025 | |
| Celgene Corporation | $22,702.93 | 2019-2021 | |
| Genentech USA, INC. | $4,304.82 | 2019-2020 | |
| Greenwich Biosciences, INC. | $2,286.00 | 2021 | |
| Emd Serono, INC. | $493.54 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $121.16 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $57.53 | 2019-2022 | |
| Horizon Therapeutics Plc | $48.80 | 2022-2023 | Uplizna |
| Banner Life Sciences, LLC | $42.05 | 2022 | |
| Lundbeck LLC | $27.47 | 2025 | Vyepti |
| Abbott Laboratories | $24.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.62 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.63 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Elkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.